SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 3 filers reported holding SAGE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,762 | -99.6% | 85,600 | +574.0% | 0.00% | +200.0% |
| Q3 2022 | $497,000 | -64.6% | 12,700 | -70.7% | 0.00% | -50.0% |
| Q2 2022 | $1,402,000 | -88.2% | 43,400 | -84.8% | 0.00% | -80.0% |
| Q2 2020 | $11,884,000 | -44.6% | 285,800 | -61.7% | 0.01% | -52.4% |
| Q1 2020 | $21,458,000 | +168.8% | 747,132 | +575.6% | 0.02% | +250.0% |
| Q4 2019 | $7,984,000 | +1916.2% | 110,591 | +3849.7% | 0.01% | – |
| Q3 2018 | $396,000 | -99.5% | 2,800 | -99.4% | 0.00% | -100.0% |
| Q2 2018 | $73,126,000 | +55.5% | 458,700 | +57.1% | 0.04% | -21.6% |
| Q1 2018 | $47,032,000 | +1145.2% | 292,000 | +1173.4% | 0.05% | +1175.0% |
| Q4 2017 | $3,777,000 | +576.9% | 22,931 | +106.6% | 0.00% | +300.0% |
| Q1 2015 | $558,000 | – | 11,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |